The Next Decade of Gene Therapy Innovation

by Kyle O’Neil and Brendan Wang with Peter Bak, PhD and Stephan Gauldie, PhD

Over the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. Contributing authors Kyle O’Neil, Brendan J. Wang, Dr. Peter Bak and Dr. Stephan Gauldie examine commercial setbacks and potential opportunities, looming delivery questions, and offer value proposition recommendations for the future of gene therapies in medicine.